Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

NCT05892614 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Interstitial Lung Disease

Interventions

DRUG: efzofitimod 450 mg
DRUG: efzofitimod 270 mg
DRUG: Placebo

Sponsor

aTyr Pharma, Inc.